Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial

sonderdruck aus: ESMO open | 2021

von Heilig, C. | Illert, A. | Schlenk, R.

Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 Phase III Study

sonderdruck aus: Journal of clinical oncology | 2020

von Schlenk, R. | Lübbert, M. | Döhner, H.

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia

sonderdruck aus: Blood cancer journal | 2017

von Jaramillo, S. | Lübbert, M. | Schlenk, R.

Identifying prognostic SNPs in clinical cohorts: complementing univariate analyses by resampling and multivariable modeling

sonderdruck aus: PLOS ONE | 2016

von Hieke-Schulz, S. | Benner, A. | Schlenk, R. | +3

Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia - Ongoing Trials

Erschienen: Basel, Karger, 2007

von Gleissner, B. | Schlenk, R. | Bornhäuser, M. | +1